Cytosponge for Gastric Intestinal Metaplasia

RecruitingOBSERVATIONAL
Enrollment

226

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Gastric CancerGastric Intestinal MetaplasiaGastric Atrophy
Interventions
DEVICE

Cytosponge-TFF3

Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.

Trial Locations (1)

CB20QQ

RECRUITING

Cambridge Clinical Research Centre, Cambridge

All Listed Sponsors
collaborator

University College London Hospitals

OTHER

collaborator

Nottingham University Hospitals NHS Trust

OTHER

lead

University of Cambridge

OTHER